The FDA will finish September with three action dates and one of the year’s most highly-anticipated advisory committee meetings.
Posts
BrainStorm Cell Therapeutics concluded 2022 on a cautiously optimistic note as the FDA granted a Type A meeting to discuss the refuse to file letter it served the Israel and New York-based biotech in November for its ALS hopeful, NurOwn. On Wednesday, the company made a series of C-suite moves in what could be a show of confidence in NurOwn’s ability to prevail.
